Effect of simvastatin on the transforming growth factor β1, fibroscan scores, and aspartate transaminase to platelet index ratio patients with Liver Cirrhosis
Loading...
Date
2018-03
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Society of Paediatric, Gastroenterology, Hepatobiliary, Transplant and Nutrition
Abstract
Background: Cirrhosis of the liver is the liver disorder marked fibrosis and abnormal liver architecture. Treatment of liver cirrhosis, among others, is to reduce fibrogenesis. Simvastatin as an anti-fibrotic among others, by a mechanism reduce the activity of hepatic stellate cell of the liver, reduce cell proliferation liver stelat, increases the production of nitric oxide and decrease vascular resistance in the liver cirrhosis. Aim: This research to determine effect of simvastatin on the transforming growth factor β1, fibroscan scores, and aspartate transaminase to platelet index ratio patients with liver cirrhosis. Methods: This study is a randomized experiment, a sample of 30 people, divided into a control group given a placebo and the treatment given simvastatin 20 mg / day orally for 4 weeks. Before and after treatment measured levels of TGF β1, FibroScan score, and a score of APRI. Statistical analysis using SPSS 22 for windows. Two different test mean using parametric tests (independent t test, paired t test) and if the data is normally distributed variable or non-parametric tests (Mann-Whitney / Wilcoxon Signed Rank Test). P significant if p <0.05. Results: The results showed that the administration of simvastatin 20 mg for 4 weeks will reduce levels TGF β1 (20,98+7,80 µg/dl pretreatment, 16,20+5,50µg/dl post treatment; p=0,013), reduce fibroscan scores (22,29+14,65 kpa pretreatment, 13,61+4,02 kpa post treatment; p=0,049) and reduce APRI scores (40,13+41,28 pretreatment, 23,41+17,61 post treatment; p=0,002). Conclusion: This study demonstrated that administration Simvastatin will be reduced levels of the transforming growth factor β1, fibroscan scores, and aspartate transaminase to platelet index ratio patients with liver cirrhosis.
Description
Keywords
Simvastatin, Transforming Growth Factor β1, Fibroscan score, Aspartate Transaminase To Platelet Index Ratio, Liver Cirrhosis
Citation
Kusnanto P., Prabowo NA, Bambang P. Effect of simvastatin on the transforming growth factor β1, fibroscan scores, and aspartate transaminase to platelet index ratio patients with Liver Cirrhosis. International Journal of Gastroenterology, Hepatology, Transplant & Nutrition. 2018 Mar; 3(1): 1-7